Bristol Myers Squibb Doubles Down on AI

What happened: Pharmaceutical giant Bristol Myers Squibb (BMS) just announced they're deploying their second NVIDIA DGX SuperPOD — this one built on the new Vera Rubin architecture. They're calling it the "SuperDuperPOD," and it's now the most powerful AI cluster in life sciences.

The numbers:

• 8 DGX Vera Rubin NVL72 systems
• 10x performance per megawatt vs. what it replaces
• Every scientist gets access — no wait times, no limits
• 3 years of AI-driven drug discovery already under their belt

Why this matters beyond pharma:

BMS is proving a template for how established enterprises should adopt AI:

• Democratize access. They opened their first SuperPOD to "literally every scientist." Restricted access kills adoption.
• Think in workflows, not tasks. They're using agentic workflows across the full pipeline — not one-off predictions.
• Measure in cycles, not hype. Three years in, they're doubling down because they've seen results.

The NYC connection: BMS has major operations in the NYC area. More hiring, more AI talent, more proof that enterprise AI is happening now.

Bottom line: If a 140-year-old pharmaceutical company can rebuild itself around AI agents and supercomputing, what's your excuse?

───

✅ Source verified: NVIDIA Blog, August 6, 2026